NYSEAMERICAN : IBO
Impact BioMedical Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.87 USD (Oct 30, 2026, 9:38 AM EDT) · Market cap 33.06M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 32.47M |
| Enterprise Value | 32.46M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 8.54M |
| Shares Outstanding | 8.54M |
| Shares Change (YoY) | +571.61% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 2.78% |
| Owned by Institutions (%) | 3.56% |
| Float | 910,314 |
Ratios
| Measure | Value |
|---|
| PE Ratio | 57.36 |
| Forward PE | n/a |
| PS Ratio | 927.61 |
| Forward PS | n/a |
| PB Ratio | 3.02 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 41.03 |
| EV / Sales | 927.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.16 |
| Quick Ratio | 0.00 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -19.45 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 23.46% |
| Return on Assets (ROA) | -17.79% |
| Return on Invested Capital (ROIC) | -21.97% |
| Return on Capital Employed (ROCE) | -34.66% |
| Weighted Average Cost of Capital (WACC) | 19.29% |
| Revenue Per Employee | $17,500 |
| Profits Per Employee | $395,500 |
| Employee Count | 2 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 1.55 |
Taxes
| Measure | Value |
|---|
| Income Tax | -2.58M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.73 |
| 52-Week Price Change | -47.16% |
| 50-Day Moving Average | 5.16 |
| 200-Day Moving Average | 6.26 |
| Relative Strength Index (RSI) | 43.44 |
| Average Volume (20 Days) | 17,810 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 26,292 |
| Short Previous Month | 41,758 |
| Short % of Shares Out | 0.31% |
| Short % of Float | 2.89% |
| Short Ratio (days to cover) | 1.90 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 35,000 |
| Gross Profit | -389,000 |
| Operating Income | -5.10M |
| Pretax Income | -1.80M |
| Net Income | 791,000 |
| EBITDA | -3.95M |
| EBIT | -5.10M |
| Earnings Per Share (EPS) | $0.07 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 10,000 |
| Total Debt | n/a |
| Net Cash | 10,000 |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | 14.01M |
| Book Value Per Share | 1.26 |
| Working Capital | -1.73M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -508,000 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.14M |
| Net Borrowing | -109,000 |
| Free Cash Flow | -508,000 |
| FCF Per Share | -$0.06 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -14,557.14% |
| Pretax Margin | -5,148.57% |
| Profit Margin | 2,260.00% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -571.61% |
| Shareholder Yield | -571.61% |
| Earnings Yield | 1.74% |
| FCF Yield | -1.56% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 23, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:12.62 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |